EpiCept Reports Fourth Quarter and Full Year 2010 Operating and Financial Results


EpiCept Reports Fourth Quarter and Full Year 2010 Operating and
Financial Results

Conference Call to Be Held at 9:00 A.M. Eastern Time Today

TARRYTOWN, N.Y.--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

EpiCept Corporation (Nasdaq and Nasdaq OMX Stockholm Exchange: EPCT)
today announced operating and financial results for the fourth quarter
and full year ended December 31, 2010, and provided an update on its key
business initiatives.

“EpiCept marked several important achievements since our last quarterly
report,” stated Jack Talley, EpiCept President and CEO. “We are
delighted with the excellent clinical data we recently reported from the
EpiCeptTM NP-1 trial studying chemotherapy-induced peripheral neuropathy
(CIPN), which we believe confirms NP-1's utility in meeting a high unmet
medical need in a large patient population. We also made important
progress late last year by gaining agreement with the U.S. Food and Drug
Administration that a trial for Ceplene®/IL-2 with survival as the
primary endpoint need not isolate the contribution of Ceplene® in the
regimen, but would need to show a statistically significant overall
survival advantage for remission maintenance of patients suffering from
acute myeloid leukemia. We believe this study has a very good
probability of success. We are also closely following Meda's marketing
of Ceplene® in the European Union and believe that they are pursuing a
determined course of action that will ultimately result in significant
penetration into the EU medical community.”

Business Update

  · Ceplene® - approved in the European Union (EU) and Israel for
administration with low-dose interleukin-2 (IL-2) for the remission
maintenance and prevention of relapse of patients with Acute Myeloid
Leukemia (AML) in first remission; AML is the most deadly form of
leukemia in adults. The product has been licensed to Meda AB of Sweden
to market and sell in Europe and certain Pacific Rim countries, and to
MegaPharm Ltd. to market and sell in Israel.

In October 2010, EpiCept reached an agreement with the FDA on a
regulatory path leading to a resubmission of a New Drug Application
(NDA) for Ceplene®. EpiCept agreed to undertake a new confirmatory
clinical trial to demonstrate Ceplene's activity in conjunction with
low-dose IL-2 as remission maintenance therapy for AML patients in first
complete remission with overall survival as the primary endpoint. The
trial will be a two-arm, randomized, open-label trial that will compare
the efficacy of Ceplene® plus low-dose IL-2 to standard of care in this
indication. EpiCept has drafted the clinical trial protocol and is now
reviewing it with key opinion leaders before submitting it to the FDA.
EpiCept expects to submit the protocol shortly following which the FDA,
via the Special Protocol Assessment procedure, will provide guidance on
specific sections of the protocol. The Company expects to begin the
trial in the second half of 2011. Ceplene® has been granted orphan drug
status in the United States, which provides seven years of market
exclusivity from the approval date.

EpiCept believes that Ceplene's prospects for achieving a positive
result in this confirmatory trial are very good. The previous Phase III
trial demonstrated a statistically significant prolongation of the
primary endpoint of leukemia-free survival and an advantage in increased
overall survival of more than an extra year of life in all patients
studied in their first complete remission. In December 2010, EpiCept
released the results of a new subset analysis of 190 patients from this
trial that were treated aggressively with consolidation therapy before
being randomized. Within this subset of patients, a difference in
overall patient survival was seen in favor of Ceplene®/IL-2 versus
standard of care (p= 0.07, with a median overall benefit of more than 36
months). This outcome suggests that statistically significant improved
overall survival could be achieved in a well designed and adequately
powered clinical trial.

During 2010, EpiCept's appeal of a decision by Health Canada not to
provide data protection for Ceplene® was denied by a federal court in
Canada. Lack of data protection in Canada for an innovative drug such as
Ceplene® eliminates any right to sales exclusivity by EpiCept and
enables competition to seek approval to sell generic equivalents
immediately. In November 2010, EpiCept appealed the court's decision and
withdrew its New Drug Submission until the appeals process is completed.
EpiCept has been joined in its appeal of this decision by Canada's Rx&D,
a national industry association representing 50 research-based
pharmaceutical companies in Canada. The Company retains the right to
re-file the application at any time over the next five years without
prejudice.

In Europe, Meda is concentrating on gaining patient access to Ceplene®
through its inclusion in clinical trials that are being conducted by key
opinion leaders. Regulatory efforts include seeking reimbursement
approvals in France, Spain, Italy and smaller markets in the EU, and
filing for marketing approval in non-EU European and Pacific Rim
countries. Reimbursement approvals are expected during 2011 and several
marketing applications are expected to be submitted in the first half of
2011. Sales of Ceplene® were not material in the fourth quarter of 2010
and are not expected to grow significantly until 2012.

Ceplene® was approved for marketing by Israel's Ministry of Health in
the fourth quarter of 2010. Marketing is expected to commence later this
quarter by MegaPharm.

EpiCept is continuing patient enrollment into its post-approval clinical
study with Ceplene®. Data is expected to be reported beginning in late
2011. Thirty centers across Europe are participating in this study, with
sites in Sweden, Belgium, France, the U.K., Spain, Germany and Italy.
The Company intends to use the data from this single-arm, open-label
trial to meet its post-approval commitment and to seek a refinement of
Ceplene's EU labeling. The data will also have value to prescribing
hematologists.

  · EpiCeptTM NP-1 - a prescription topical analgesic cream designed to
provide long-term relief from the pain of peripheral neuropathies, which
affect more than 15 million people in the U.S. alone. Earlier this
month, EpiCept announced positive results from a Phase IIb trial
evaluating the efficacy and safety of EpiCept™ NP-1 (NP-1) in
chemotherapy-induced peripheral neuropathy (CIPN). The multi-center,
double-blind, randomized, placebo-controlled study was conducted by the
National Cancer Institute (NCI)-funded Community Clinical Oncology
Program. More than 460 cancer survivors suffering from painful CIPN were
enrolled in the six-week study. The results of the trial in the intent
to treat (ITT) population demonstrated that the change in average daily
neuropathy intensity scores in the NP-1 group achieved a statistically
significant reduction in CIPN intensity versus placebo (p<0.001), which
was the trial's primary endpoint. Additionally, a pre-specified subgroup
of the ITT population, those patients who previously received taxane
chemotherapy, also showed a statistically significant reduction in
average daily neuropathy intensity scores (p=0.034). This subgroup
constituted more than 50% of the ITT population. Secondary efficacy
endpoints confirmed the superiority of NP-1 vs. placebo. Furthermore,
the safety profile of NP-1 was comparable to placebo.

The NCI estimates that 30-40% of cancer patients treated with
chemotherapy experience symptoms of CIPN, which impairs their quality of
life and ability to function. The debilitating, chronic pain of CIPN is
one of the most common reasons why cancer patients discontinue their
treatment prematurely. More than one million breast cancer survivors in
the United States alone suffer from this disease, for which there is no
effective therapy.

The results of this trial build upon EpiCept's clinical development of
NP-1 in both diabetic and post-herpetic neuropathies. The Company has
enrolled more than 1,700 patients into clinical trials of NP-1,
including a 360-patient trial that studied NP-1's efficacy compared with
gabapentin and placebo in post-herpetic neuropathy, for which positive
results were previously reported. As previously reported, EpiCept
intends to partner NP-1 prior to the commencement of the Phase III
program in order to share the costs and development risk, and ultimately
to have that partner market the product globally upon approval. Partner
discussions are continuing.

  · CrolibulinTM - a vascular disruption agent that has demonstrated
potent anti-tumor activity in both preclinical and early clinical
studies. In December 2010, the NCI initiated a Phase II trial for
crolibulinTM to assess safety and efficacy in combination with cisplatin
in patients with anaplastic thyroid cancer (ATC). Trial enrollment has
commenced and data from this trial could be available as early as late
in 2011.
  · Azixa™ - a compound discovered by EpiCept and licensed to Myrexis as
part of an exclusive, worldwide development and commercialization
agreement. Myrexis is currently conducting Phase II trials with Azixa™.
Updated results from an ongoing, open-label Phase IIa monotherapy study
of Azixa™ in treatment-experienced patients with glioblastoma multiforme
(GBM), an aggressive brain tumor, were presented in November 2010
demonstrating durable responses in patients who had failed both first-
and second- line therapy. Data from a sub-group of patients with
recurrent GBM who are naïve to Avastin is expected to be reported in the
first half of 2011. In December 2010, Myrexis began a Phase IIb clinical
study of AzixaTM to treat GBM. The study will enroll as many as 120
patients in the U.S. and India in order to evaluate AzixaTM combination
therapy as a first-line GBM treatment. AzixaTM has received orphan drug
status in the United States for the treatment of glioblastoma. The
dosing of the first patient in a Phase III trial for Azixa™ triggers a
milestone payment to EpiCept.

Financial and Operating Highlights

EpiCept's net loss for the fourth quarter of 2010 was $3.0 million, or
$0.06 per share, and for the year was $15.5 million, or $0.32 per share.
As of December 31, 2010, EpiCept had approximately 55.0 million shares
outstanding. EpiCept's loss per share and shares outstanding reflect a
1:3 reverse split that was effected in January 2010.

Fourth Quarter 2010 vs. Fourth Quarter 2009

Revenue

The Company recognized revenue of $0.3 million during the fourth quarter
of 2010, an increase of $0.2 million compared with $0.1 million in the
fourth quarter of 2009. The increase was primarily related to $0.1
million in product revenue from the sales of Ceplene® in 2010 and an
increase of $0.1 million in the recognition of license fee payments
previously received from the Company's partners.

Cost of Goods Sold

Cost of goods sold in the fourth quarter of 2010 was $0.6 million,
consisting primarily of a $0.5 million expense for Ceplene® inventory
the Company believes will not be sold prior to reaching its product
expiration date.

Selling, General and Administrative Expense

Selling, general and administrative expense in the fourth quarter of
2010 decreased by 15%, or $0.3 million, to $1.6 million compared with
$1.9 million in the fourth quarter of 2009. The decrease was primarily
related to lower investor relations, public reporting and stock-based
compensation expenses.

Research and Development Expense

Research and development expense in the fourth quarter of 2010 decreased
by approximately 39%, or $0.9 million, to $1.5 million compared with
$2.4 million in the fourth quarter of 2009. The decrease was primarily
related to lower clinical trial and regulatory expenses for Ceplene®.

Other Income (Expense)

Other income (expense) during the fourth quarters of 2010 and 2009
amounted to net income of $0.4 million and net expense of $0.3 million,
respectively. The primary component of other income in the fourth
quarter of 2010 was a tax grant of $0.7 million received from the
Internal Revenue Service (IRS) as part of the Qualifying Therapeutic
Discovery Project Program, partially offset by interest expense and a
foreign exchange loss. The primary component of other expense in 2009
was interest expense and foreign exchange loss.

Full Year 2010 vs. Full Year 2009

Revenue

During the years 2010 and 2009, the Company recognized deferred revenue
of $0.8 million and $0.4 million, respectively, and product revenue from
the sales of Ceplene® of $0.2 million and zero, respectively. During
2010, revenue was primarily related to the recognition of deferred
revenue from the Company's license agreements with its partners, as well
as royalties with respect to certain technology and sales of Ceplene®.
During 2009 revenue was primarily related to the recognition of deferred
revenue from the Company's license agreements with its partners, as well
as royalties with respect to certain technology and sales of Ceplene®.

Cost of Goods Sold

Cost of goods sold in 2010 was $1.0 million, consisting primarily of a
$0.9 million expense for Ceplene® inventory the Company believes will
not be sold prior to reaching its product expiration date.

Selling, General and Administrative (SG&A) Expense

Selling, general and administrative expense in 2010 decreased by
approximately 4%, or $0.3 million, to $7.2 million compared with $7.5
million in 2009. The decrease in SG&A expense can be attributed to lower
investor relations, public reporting and stock-based compensation
expenses.

Research and Development Expense

Research and development expense in 2010 decreased by approximately 30%,
or $3.5 million, to $8.1 million compared with $11.6 million in 2009.
The decrease compared with 2009 was primarily attributable to a $2.0
million reduction in salary and salary-related expenses and facility
costs related to the closing of the Company's research facility in San
Diego in 2009, lower clinical trial expenses for Ceplene® of $0.9
million, lower license fees of $0.5 million and lower stock-based
compensation expenses of $0.2 million, partially offset by higher
regulatory fees for Ceplene® of $0.3 million.

Other Income (Expense)

Other income (expense) during 2010 amounted to a net expense of $0.2
million compared with a net expense of $20.1 million during 2009. The
$19.9 million decrease in other expense, net was primarily related to
$10.5 million in amortization of debt issuance costs and discount and
$9.3 million in interest expense, which was paid from restricted cash,
as a result of the conversion of $24.5 million of the Company's 7.5556%
convertible subordinated notes due 2014 into approximately 9.1 million
shares of common stock in 2009. Other income (expense) was negatively
impacted by a $0.5 million foreign exchange loss in 2010, compared with
a $0.2 million foreign exchange gain in 2009. The Company received a
$0.7 million tax grant in 2010 from the IRS as part of the Qualifying
Therapeutic Discovery Project Program.

EpiCept also announced today that in its Annual Report on Form 10-K for
the year ended December 31, 2010, the Company's independent registered
public accounting firm is expected to express an unqualified opinion on
the December 31, 2010 consolidated financial statements and will include
an explanatory paragraph expressing substantial doubt about the
Company's ability to continue as a going concern.

Liquidity

As of December 31, 2010 EpiCept had approximately $2.4 million in cash
and cash equivalents. Subsequent to the end of the year, in February
2011, the Company announced that it received approximately $6.6 million
in net proceeds from the issuance of approximately 8.9 million shares of
its common stock at $0.80 per share, and five-year warrants to purchase
up to approximately 3.6 million shares of common stock at an exercise
price of $0.75 per share. The Company believes that its current cash is
sufficient to fund operations through the third quarter of 2011.

In November 2010, the Company provided an update on its efforts to
finance the Company's operations beyond 2010. The key element of the
Company's plan is a non-equity financing transaction that, if completed,
will support its current operations well into 2012. The completion of
this transaction was delayed by due diligence and other considerations
and, while EpiCept is continuing its efforts to secure this financing,
there is no assurance that it will be completed. The Company may
determine to seek additional or alternative sources or types of
financing should the transaction not close or the proceeds are less than
anticipated. The Company may receive cash from certain licensing
activities during 2011.

Conference Call

EpiCept will host a conference call to discuss these results and answer
questions on February 24, 2011 beginning at 9:00 a.m. Eastern Standard
Time.

To participate in the live call, please dial from the United States or
Canada (877) 809-8594 or from international locations (706) 758-9407
(please reference access code 46419978). The conference call will also
be broadcast live in listen-only mode on the Internet and may be
accessed at
www.epicept.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http
%3A%2F%2Fwww.epicept.com&esheet=6624046&lan=en-US&anchor=www.epicept.com
&index=1&md5=c836176e6bc1710dc46d496590a15f27). The webcast will be
archived for 90 days.

A telephone replay of the call will be available for seven days by
dialing from the United States or Canada (800) 642-1687 or from
international locations (706) 645-9291 (please reference reservation
number 46419978).

About EpiCept Corporation

EpiCept is focused on the development and commercialization of
pharmaceutical products for the treatment of cancer and pain. The
Company's lead product is Ceplene®, approved in the EU and Israel for
the remission maintenance and prevention of relapse in adult patients
with Acute Myeloid Leukemia (AML) in first remission. In the United
States, a pivotal trial is scheduled to commence in 2011. The Company
has two other oncology drug candidates currently in clinical development
that were discovered using in-house technology and have been shown to
act as vascular disruption agents in a variety of solid tumors. The
Company's pain portfolio includes EpiCept™ NP-1, a prescription topical
analgesic cream in late-stage clinical development designed to provide
effective long-term relief of pain associated with peripheral
neuropathies.

Forward-Looking Statements

This news release and any oral statements made with respect to the
information contained in this news release contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include statements
that express plans, anticipation, intent, contingency, goals, targets,
future development and are otherwise not statements of historical fact.
These statements are based on our current expectations and are subject
to risks and uncertainties that could cause actual results or
developments to be materially different from historical results or from
any future results expressed or implied by such forward-looking
statements. Factors that may cause actual results or developments to
differ materially include: the risk that Ceplene® will not receive
regulatory approval or marketing authorization in the United States, the
risk that Ceplene® will not achieve significant commercial success, the
risk that any required post-approval clinical study for Ceplene® will
not be successful, the risk that we will not be able to maintain our
final regulatory approval or marketing authorization for Ceplene®, the
risk that future financing will not successfully close or that the
proceeds thereof will be materially less than anticipated, the risks
associated with the adequacy of our existing cash resources and our
ability to continue as a going concern, the risks associated with our
ability to continue to meet our obligations under our existing debt
agreements, the risk that Azixa™ will not receive regulatory approval or
achieve significant commercial success, the risk that we will not
receive any significant payments under our agreement with Myrexis, the
risk that the development of our other apoptosis product candidates will
not be successful, the risk that clinical trials for EpiCept™ NP-1 or
crolibulinTM will not be successful, the risk that EpiCept™ NP-1 or
crolibulinTM will not receive regulatory approval or achieve significant
commercial success, the risk that we will not be able to find a partner
to help conduct the Phase III trials for EpiCept™ NP-1 on attractive
terms, a timely basis or at all, the risk that our other product
candidates that appeared promising in early research and clinical trials
do not demonstrate safety and/or efficacy in larger-scale or later stage
clinical trials, the risk that we will not obtain approval to market any
of our product candidates, the risk that our securities may be delisted
from Nasdaq; the risks associated with dependence upon key personnel,
the risks associated with reliance on collaborative partners and others
for further clinical trials, development, manufacturing and
commercialization of our product candidates; the cost, delays and
uncertainties associated with our scientific research, product
development, clinical trials and regulatory approval process; our
history of operating losses since our inception; the highly competitive
nature of our business; risks associated with litigation; and risks
associated with our ability to protect our intellectual property. These
factors and other material risks are more fully discussed in our
periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and
other filings with the U.S. Securities and Exchange Commission. You are
urged to carefully review and consider the disclosures found in our
filings which are available at
www.sec.gov (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%
2F%2Fus.lrd.yahoo.com%2F_ylt%3DAgfqFPfVOEK5M4_Rv8aJvhTjba9_%3B_ylu%3DX3o
DMTEzM2pvaWgxBHBvcwMyBHNlYwNuZXdzYXJ0Ym9keQRzbGsDd3d3c2VjZ292%2FSIG%3D15
t064n6f%2F**http%253A%2Fcts.businesswire.com%2Fct%2FCT%253Fid%3Dsmartlin
k%2526url%3Dhttp%25253A%25252F%25252Fwww.sec.gov%2526esheet%3D6170045%25
26lan%3Den_US%2526anchor%3Dwww.sec.gov%2526index%3D2%2526md5%3D61ec7b720
44301e411e3335754ee5c07&esheet=6624046&lan=en-US&anchor=www.sec.gov&inde
x=2&md5=aaa413e96866926ef5de09ace0b05704) or at
www.epicept.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http
%3A%2F%2Fus.lrd.yahoo.com%2F_ylt%3DAhBuoawHw6iS3RhJOH9dNNfjba9_%3B_ylu%3
DX3oDMTE2OGhhcWs4BHBvcwMzBHNlYwNuZXdzYXJ0Ym9keQRzbGsDd3d3ZXBpY2VwdGNv%2F
SIG%3D1659oglun%2F**http%253A%2Fcts.businesswire.com%2Fct%2FCT%253Fid%3D
smartlink%2526url%3Dhttp%25253A%25252F%25252Fwww.epicept.com%2526esheet%
3D6170045%2526lan%3Den_US%2526anchor%3Dwww.epicept.com%2526index%3D3%252
6md5%3D8b3a48c3367e26fcfbd15295b6d82118&esheet=6624046&lan=en-US&anchor=
www.epicept.com&index=3&md5=035b633cc9fb2c1c34279248ba8d3818). You are
cautioned not to place undue reliance on any forward-looking statements,
any of which could turn out to be wrong due to inaccurate assumptions,
unknown risks or uncertainties or other risk factors.

Selected financial information follows:

EpiCept Corporation and Subsidiaries
(Unaudited)
Selected Consolidated Balance Sheet Data
(in $000s)
                                                   December 31,
                                                   2010             
2009
                                                                      
Cash and cash equivalents                          $  2,435          $ 
5,142
Property and equipment, net                           222              
360
Total assets                                       $  4,689          $ 
7,514
                                                                      
Accounts payable and other accrued liabilities     $  3,389          $ 
4,054
Deferred revenue                                      13,826           
9,622
Notes and loans payable                               972              
1,952
Total stockholders' deficit                           (14,135  )       
(9,079  )
Total liabilities and stockholders' deficit        $  4,689          $ 
7,514

EpiCept Corporation and Subsidiaries
(Unaudited)
Selected Consolidated Statement of Operations Data
(in $000s except share and per share data)
                                                                        
                
                                                 Three Months Ended
December 31,           Year Ended December 31,
                                                 2010                
2009                 2010                 2009
                                                                        
                                        
Revenue                                          $  291               $ 
92                $  994               $  414          
Operating expenses:
Cost of goods sold                                  573                 
—                    997                  —
General and administrative                          1,612               
1,896                7,244                7,548
Research and development                            1,459               
2,382                8,127                11,603       
Total operating expenses                            3,644               
4,278                16,368               19,151       
Loss from operations                                (3,353      )       
(4,186      )        (15,374     )        (18,737     )
Other income (expense):
Interest income                                     1                   
6                    7                    32
Foreign exchange gain (loss)                        (180        )       
(140        )        (538        )        221
Interest expense                                    (173        )       
(116        )        (361        )        (20,021     )
Miscellaneous income                                733                 
—                    733                  (305        )
Other income (expense), net                         381                 
(250        )        (159        )        (20,073     )
Net loss before income taxes                        (2,972      )       
(4,436      )        (15,533     )        (38,810     )
Income taxes                                        —                   
—                    (4          )        (4          )
Net loss                                         $  (2,972      )     $ 
(4,436      )     $  (15,537     )     $  (38,814     )
Basic and diluted loss per common share          $  (0.06       )     $ 
(0.10       )     $  (0.32       )     $  (0.97       )
Weighted average common shares outstanding *        52,466,655          
44,031,387           47,853,560           40,139,299
                                                                        
                                                       
* Reflects a 1:3 reverse split effected in January 2010.

EpiCept Corporation and Subsidiaries
(Unaudited)
Selected Consolidated Statement of Cash Flows Data
(in $000s)
                                                       
                                                         Year Ended
December 31,
                                                         2010          
   2009
                                                                        
   
Net cash used in operating activities                    $  (10,400  )  
  $  (29,453  )
Net cash provided by (used in) investing activities         63          
     (52      )
Net cash provided by financing activities                   7,637       
     33,874
Effect of exchange rate changes on cash                     (7       )  
     (17      )
Net increase (decrease) in cash and cash equivalents        (2,707   )  
     4,352
Cash and cash equivalents at beginning of year              5,142       
     790       
Cash and cash equivalents at end of year                 $  2,435       
  $  5,142     

EpiCept Corporation and Subsidiaries
(Unaudited)
Selected Consolidated Statement of Stockholders Deficit Data
(in $000s)
                                                                        
          
                                                                   Year
Ended December 31,
                                                                   2010 
            2009
                                                                        
             
Stockholders' deficit at beginning of year                         $ 
(9,079   )     $  (17,730  )
                                                                        
             
Net loss for the period                                              
(15,537  )        (38,814  )
Stock-based compensation expense                                     
959               1,470
Foreign currency translation adjustment                              
661               (293     )
Share and warrant issuance                                           
8,088             15,677
Exercise of options and warrants                                     
773               3,823
Reclassification of warrants from liability to equity, net            — 
               2,288
Conversion of convertible subordinated notes into common stock        — 
               24,500    
                                                                        
             
Stockholders' deficit at end of year                               $ 
(14,135  )     $  (9,079   )

As of February 24, 2011, EpiCept had approximately 63.9 million shares
outstanding.

# # #

*Azixa is a registered trademark of Myrexis, Inc.

EPCT-GEN

EpiCept Corporation:
Robert W. Cook, 914-606-3500
rcook@epicept.com (rcook@epicept.com)
or
Media:
Feinstein Kean Healthcare
Greg Kelley, 617-577-8110
gregory.kelley@fkhealth.com (gregory.kelley@fkhealth.com)
or
Investors:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com (kgolodetz@lhai.com)
or
Bruce Voss, 310-691-7100
bvoss@lhai.com (bvoss@lhai.com)

Pièces jointes

02242005.pdf